Clinical trial
Phase II Study of Apatinib as Third- or Further-line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
NCT02945852 is registered in ClinicalTrials.gov with Fan Yun, MD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Apatinib as Third- or Further-line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
- Lead sponsor
- Fan Yun, MD
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2016
- Completion date
- May 26, 2019
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
small cell lung cancer